Mastodawn

Pathology Slide QC AI Market Set to Reach $1.37B by 2030 🚀

The pathology slide quality control AI market is growing fast—rising from $0.53B in 2025 to $1.38B by 2030 at a 21% CAGR. Growth is driven by digital pathology adoption, higher diagnostic volumes, workflow automation, and AI-based quality assurance.

🔗 Free sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=30689&type=smp

#AI #DigitalPathology #HealthcareAI #MarketResearch

Pathology Slide Quality Control AI Market Size Report 2026 Sample

Pathology slide quality control artificial intelligence market to reach $1.38 billion by 2030 at 21.0% cagr, driven by expansion of diagnostic testing volumes.

Serdar Balci Jan 27

The Single Arm Survival tool in jamovi #jsurvival module singlearm function
analyzes overall survival characteristics for phase II trials, cancer registries, and cohort studies. Simply input time-to-event data (or diagnosis/follow-up dates) and outcome status.
#Pathology #DigitalPathology #Biostatistics #Oncology #SurvivalAnalysis #jamovi

Serdar Balcı Jan 27

The Single Arm Survival tool in jamovi #jsurvival module singlearm function
analyzes overall survival characteristics for phase II trials, cancer registries, and cohort studies. Simply input time-to-event data (or diagnosis/follow-up dates) and outcome status.
#Pathology #DigitalPathology #Biostatistics #Oncology #SurvivalAnalysis #jamovi

Smidmart Dec 25

AI Vision in Pathology: In the near future, pathology labs will look very different from the traditional model of glass slides and a single expert at a microscope.
know more:https://zurl.co/9HRFD
#AIVision #DigitalPathology #HealthcareAI #MedicalImaging #Diagnostics

Winbuzzer Dec 10

https://winbuzzer.com/2025/12/10/microsoft-and-providence-open-source-gigatime-ai-model-to-slash-cancer-research-costs-xcxwbn/

Microsoft and Providence Open-Source 'GigaTIME' AI Model to Slash Cancer Research Costs

#AI #Microsoft #HealthTech #CancerResearch #MedicalAI #OpenSource #DigitalPathology #PrecisionMedicine #GigaTIME #Biotech #Oncology #DeepLearning #ProvidenceHealth #VirtualStaining #Science

Industry Examiner Dec 9

The FDA has qualified AIM-NASH, the first AI histology tool used as a drug-development endpoint, to read liver biopsies in MASH trials. What happens when an algorithm helps decide if a drug works?
https://biotech.industryexaminer.com/fda-aim-nash-ai-liver-biopsy-mash-trials/
#biotech #AIinBiotech #liverdisease #MASH #digitalpathology #clinicaltrials #regulatoryscience #TechNews

When the FDA Starts Trusting Algorithms: What AIM-NASH Means for Liver Drug Trials - Biotech Industry Examiner

On 8 December 2025, the US Food and Drug Administration (FDA) tried to change that. It qualified AIM-NASH – an AI-based histology system developed by PathAI –

Biotech Industry Examiner

Banish Cancer Nov 17

🔬 Digital pathology is no longer the future—it’s transforming diagnostics today.
AI, molecular biology, and cloud platforms are reshaping how pathologists work. From 99% diagnostic accuracy to faster workflows and real‑time global collaboration, digital pathology is changing patient care and precision medicine.

#DigitalPathology #Oncology #AIinHealthcare #PrecisionMedicine #CancerDiagnostics #BanishCancer